A 13-person crossover trial found higher ketone concentrations with dapagliflozin, without changing the primary GLP-1 endpoint. This is not a safety endorsement.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
HISTORI tested semaglutide in schizophrenia with prediabetes and obesity. Review HbA1c and weight effects, gastrointestinal harms and psychiatric limitations.
A 25-person crossover trial studied dairy, meal timing and circadian genes in type 2 diabetes. Glycaemic changes were secondary and require cautious interpretation.
In a two-center randomized trial, diabetes-team CGM-guided insulin titration increased inpatient time in range from 62.7% to 77.6% versus point-of-care glucose testing.
In a phase 3 noninferiority trial, an AI-led Diabetes Prevention Program was noninferior to human coaching for a 12-month composite of weight, physical activity and HbA1c outcomes.
In a 40-week phase 3 trial in China, tirzepatide 10 mg or 15 mg added to basal insulin reduced HbA1c more than placebo, with mainly mild or moderate gastrointestinal events.
A randomized crossover clamp study found that hypoglycemia prolonged QTc, with recovery by 90 minutes after euglycemia and no effect from mineralocorticoid receptor blockade.
A 12-week sleep intervention did not improve HbA1c, CGM metrics or objective sleep versus attention control in adults with type 1 diabetes; a lower HbA1c appeared only with baseline HbA1c of 7% or above.
In the 3-year PRISM trial (n=884), a precision-medicine programme doubled attainment of three or more treatment targets but did not reduce diabetes complications in Chinese adults with young-onset diabetes.
In the prespecified VESALIUS-CV diabetes subgroup (n=3655), evolocumab lowered LDL-C to 52 vs 111 mg/dL and reduced first major cardiovascular events (HR 0.69; 95% CI 0.52 to 0.91).